Abstract
K+ Channels form the largest family among ion channels. Besides regulating many physiological functions, K+ channels, being aberrantly expressed in different types of tumors, affect several hallmarks of cancer. In cancer cells, K+ channel activity regulates cell proliferation, resistance to apoptotic cell death, tumor angiogenesis, invasiveness and metastatic spread. Moreover, being expressed in cells of the tumor microenvironment, K+ channels can also modulate the immune/inflammatory response which contributes to drive cancer establishment and progression. After almost 30 years of studies, some K+ channels are emerging as novel cancer biomarkers, to be employed to stratify patients for either prognostic or predictive purposes. Moreover, it is not remote the time in which it will be possible to target specific K+ channels in cancer for therapeutic purposes. One hindrance for applying a K+ channel-based therapy to cancer is the fact that K+ channel blockers can cause side effects, which often overlap with, but can mask, benefits. We here show some strategies to overcome harmful side effects caused by blocking K+ channels. Once taken into account these strategies, K+ channels may represent suitable and easily accessible cancer biomarkers and targets for therapy. The relevant patents related to K+ channels and cancer are discussed.
Keywords: Cancer biomarkers, cancer therapy, hallmarks of cancer, ion channel pharmacology, K+ channels, KV 11.1
Recent Patents on Anti-Cancer Drug Discovery
Title:Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Volume: 8 Issue: 1
Author(s): Massimo D’Amico, Luca Gasparoli and Annarosa Arcangeli
Affiliation:
Keywords: Cancer biomarkers, cancer therapy, hallmarks of cancer, ion channel pharmacology, K+ channels, KV 11.1
Abstract: K+ Channels form the largest family among ion channels. Besides regulating many physiological functions, K+ channels, being aberrantly expressed in different types of tumors, affect several hallmarks of cancer. In cancer cells, K+ channel activity regulates cell proliferation, resistance to apoptotic cell death, tumor angiogenesis, invasiveness and metastatic spread. Moreover, being expressed in cells of the tumor microenvironment, K+ channels can also modulate the immune/inflammatory response which contributes to drive cancer establishment and progression. After almost 30 years of studies, some K+ channels are emerging as novel cancer biomarkers, to be employed to stratify patients for either prognostic or predictive purposes. Moreover, it is not remote the time in which it will be possible to target specific K+ channels in cancer for therapeutic purposes. One hindrance for applying a K+ channel-based therapy to cancer is the fact that K+ channel blockers can cause side effects, which often overlap with, but can mask, benefits. We here show some strategies to overcome harmful side effects caused by blocking K+ channels. Once taken into account these strategies, K+ channels may represent suitable and easily accessible cancer biomarkers and targets for therapy. The relevant patents related to K+ channels and cancer are discussed.
Export Options
About this article
Cite this article as:
D’Amico Massimo, Gasparoli Luca and Arcangeli Annarosa, Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (1) . https://dx.doi.org/10.2174/1574892811308010053
DOI https://dx.doi.org/10.2174/1574892811308010053 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Counteracting Oxidative Stress in Pregnancy through Modulation of Maternal Micronutrients and Omega-3 Fatty Acids
Current Medicinal Chemistry Pharmacological Exploitation of Indole-3-Carbinol to Develop Potent Antitumor Agents
Mini-Reviews in Medicinal Chemistry PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Physical Activity and Cancer Prevention: Updating the Evidence. The Role of Oxidative Stress in Carcinogenesis
Current Cancer Therapy Reviews Involvement of Nucleotide Excision and Mismatch Repair Mechanisms in Double Strand Break Repair
Current Genomics Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers
Current Medicinal Chemistry Antimicrobial, Antineoplastic and Cytotoxic Activities of Indole Alkaloids from Tabernaemontana divaricata (L.) R.Br.
Current Pharmaceutical Analysis Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Familial Colorectal Cancer Type X
Current Genomics Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Application of Reproductive Hormone Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology The Role of Estrogen and Estrogen-Related Drugs in Cardiovascular Diseases
Current Drug Metabolism Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design bHLH Transcription Factors Inhibitors for Cancer Therapy: General Features for In Silico Drug Design
Current Medicinal Chemistry Recent Developments of Steroid Sulfatase Inhibitors as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry